Epitalon
Epitalon is a four-amino-acid peptide promoted for longevity, telomeres and sleep. Its best-known results are in cell cultures. Human evidence is limited to small studies, mostly from the research group that created it.
- Legal lane: compounded on prescription under the October 2026 interim policy. Not FDA-approved.
- Evidence grade: C
- Form covered by the policy: Epitalon acetate as an injection under the skin or into muscle, in intermittent courses
- Established human dose: none
What it is
Epitalon, also spelled Epithalon, is a synthetic chain of four amino acids. It was developed by the Russian researcher Vladimir Khavinson as a lab-made counterpart to epithalamin, an extract of the pineal gland.
The two are chemically distinct. Much of the human "longevity" research people cite, including a long-running study in elderly patients, used epithalamin, not Epitalon. Evidence for one should not be treated as evidence for the other.
What the evidence shows
- Cells: Epitalon switched on telomerase and lengthened telomeres in human cell cultures. An independent lab reproduced that in 2025.
- Animals: some studies report effects on lifespan and melatonin.
- People: small studies of physiology and biomarkers, and an older report in the eye disease retinitis pigmentosa. Recent reviews found no randomized controlled trials, no studies of how the body processes the drug, and no dose-ranging studies.
Nearly all of the research comes from one group, with little independent confirmation. The July 2026 FDA advisory committee reviewed Epitalon for insomnia and recommended it.
Legal status
Epitalon left the FDA's restricted category in April 2026 and is covered by the HHS interim policy published October 30, 2026, which allows state-licensed pharmacies to compound it on an individual prescription. The policy is not approval and can be revised.
Reported dosing
No dose has been established in human trials. Reviewers describe the missing dose-ranging and absorption data as a barrier to choosing any dose.
The policy describes use in intermittent courses, not continuous daily use. We have not found a commonly quoted figure that traces to a published human dose-finding study, so we are not repeating one. If a clinician prescribes Epitalon, the prescription sets the dose and course length.
Safety
- No dedicated human safety studies have been published.
- Because Epitalon acts on telomerase, which cancer cells also use, reviewers flag a theoretical long-term cancer question that has not been answered either way.
Sources
- Epitalon and epithalamin: mechanisms, evidence and gaps (review preprint, 2026)
- Epitalon in regenerative and longevity medicine (review preprint, 2026)
- Epitalon research profile: cell studies and independence of the evidence
- GoodRx: FDA developments on peptides (policy forms and routes; committee votes)